Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Inflammation
Published in: Journal of Inflammation 1/2005

Open Access 01-12-2005 | Research

Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response

Authors: Mirko Ritter, Detlev Mennerich, Andreas Weith, Peter Seither

Published in: Journal of Inflammation | Issue 1/2005

Login to get access

Abstract

Background

Bacterial and viral exacerbations play a crucial role in a variety of lung diseases including COPD or asthma. Since the lung epithelium is a major source of various inflammatory mediators that affect the immune response, we analyzed the inflammatory reaction of primary lung epithelial cells to different microbial molecules that are recognized by Toll-like receptors (TLR).

Methods

The effects of TLR ligands on primary small airway epithelial cells were analyzed in detail with respect to cytokine, chemokine and matrix metalloproteinase secretion. In addition, the regulation of the expression of TLRs and their adaptor proteins in small airway epithelial cells was investigated.

Results

Our data demonstrate that poly(I:C), a synthetic analog of viral dsRNA, mediated the strongest proinflammatory effects among the tested ligands, including an increased secretion of IL-6, IL-8, TNF-α, GM-CSF, GRO-α, TARC, MCP-1, MIP-3α, RANTES, IFN-β, IP-10 and ITAC as well as an increased release of MMP-1, MMP-8, MMP-9, MMP-10 and MMP-13. Furthermore, our data show that poly(I:C) as well as type-1 and type-2 cytokines have a pronounced effect on the expression of TLRs and molecules involved in TLR signaling in small airway epithelial cells. Poly(I:C) induced an elevated expression of TLR1, TLR2 and TLR3 and increased the gene expression of the general TLR adaptor MyD88 and IRAK-2. Simultaneously, poly(I:C) decreased the expression of TLR5, TLR6 and TOLLIP.

Conclusion

Poly(I:C), an analog of viral dsRNA and a TLR3 ligand, triggers a strong inflammatory response in small airway epithelial cells that is likely to contribute to viral exacerbations of pulmonary diseases like asthma or COPD. The pronounced effects of poly(I:C) on the expression of Toll-like receptors and molecules involved in TLR signaling is assumed to influence the immune response of the lung epithelium to viral and bacterial infections. Likewise, the regulation of TLR expression by type-1 and type-2 cytokines is important considering the impact of exogenous and endogenous TLR ligands on Th1 or Th2 driven pulmonary inflammations like COPD or asthma, respectively.
Appendix
Available only for authorised users
Literature
1.
Bals R, Hiemstra PS: Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J. 2004, 23: 327-33. 10.1183/09031936.03.00098803.CrossRefPubMed
2.
Holgate ST, Lackie PM, Davies DE, Roche WR, Walls AF: The bronchial epithelium as a key regulator of airway inflammation and remodelling in asthma. Clin Exp Allergy. 1999, 29 (Suppl 2): 90-5. 10.1046/j.1365-2222.1999.00016.x.CrossRefPubMed
3.
Greenberg SB, Allen M, Wilson J, Atmar RL: Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000, 162: 167-73.CrossRefPubMed
4.
Zalacain R, Sobradillo V, Amilibia J, Barron J, Achotegui V, Pijoan JI, Llorente JL: Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J. 1999, 13: 343-8. 10.1034/j.1399-3003.1999.13b21.x.CrossRefPubMed
5.
Cohen L, Castro M: The role of viral respiratory infections in the pathogenesis and exacerbation of asthma. Semin Respir Infect. 2003, 18: 3-8. 10.1053/srin.2003.50001.CrossRefPubMed
6.
Hertz CJ, Wu Q, Porter EM, Zhang YJ, Weismuller KH, Godowski PJ, Ganz T, Randell SH, Modlin RL: Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human beta defensin-2. J Immunol. 2003, 171: 6820-6.CrossRefPubMed
7.
Sha Q, Truong-Tran AQ, Plitt JR, Beck LA, Schleimer RP: Activation of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol. 2004, 31: 358-64. 10.1165/rcmb.2003-0388OC.CrossRefPubMed
8.
Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, Si-Tahar M: Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem. 2005, 280: 5571-80. 10.1074/jbc.M410592200.CrossRefPubMed
9.
Takeuchi O, Hoshino K, Akira S: Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol. 2000, 165: 5392-6.CrossRefPubMed
10.
Wetzler LM: The role of Toll-like receptor 2 in microbial disease and immunity. Vaccine. 2003, 21 (Suppl 2): S55-S60. 10.1016/S0264-410X(03)00201-9.CrossRefPubMed
11.
Dabbagh K, Lewis DB: Toll-like receptors and T-helper-1/T-helper-2 responses. Curr Opin Infect Dis. 2003, 16: 199-204.CrossRefPubMed
12.
Eisenbarth SC, Piggott DA, Huleatt JW, Visintin I, Herrick CA, Bottomly K: Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med. 2002, 196: 1645-51. 10.1084/jem.20021340.PubMedCentralCrossRefPubMed
13.
Patel M, Xu D, Kewin P, Choo-Kang B, McSharry C, Thomson NC, Liew FY: TLR2 Agonist Ameliorates Established Allergic Airway Inflammation by Promoting Th1 Response and Not via Regulatory T Cells. J Immunol. 2005, 174: 7558-63.CrossRefPubMed
14.
Rodriguez D, Keller AC, Faquim-Mauro EL, de Macedo MS, Cunha FQ, Lefort J, Vargaftig BB, Russo M: Bacterial lipopolysaccharide signaling through Toll-like receptor 4 suppresses asthma-like responses via nitric oxide synthase 2 activity. J Immunol. 2003, 171: 1001-8.CrossRefPubMed
15.
Chisholm D, Libet L, Hayashi T, Horner AA: Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities. J Allergy Clin Immunol. 2004, 113: 448-54. 10.1016/j.jaci.2003.12.011.CrossRefPubMed
16.
Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T: Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun. 2002, 293: 1364-9. 10.1016/S0006-291X(02)00380-7.CrossRefPubMed
17.
Diamond G, Legarda D, Ryan LK: The innate immune response of the respiratory epithelium. Immunol Rev. 2000, 173: 27-38. 10.1034/j.1600-065X.2000.917304.x.CrossRefPubMed
18.
Yamamoto M, Takeda K, Akira S: TIR domain-containing adaptors define the specificity of TLR signaling. Mol Immunol. 2004, 40: 861-8. 10.1016/j.molimm.2003.10.006.CrossRefPubMed
19.
Janssens S, Beyaert R: Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell. 2003, 11: 293-302. 10.1016/S1097-2765(03)00053-4.CrossRefPubMed
20.
Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001, 413: 732-8. 10.1038/35099560.CrossRefPubMed
21.
Doyle S, Vaidya S, O'Connell R, Dadgostar H, Dempsey P, Wu T, Rao G, Sun R, Haberland M, Modlin R, Cheng G: RF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity. 2002, 17: 251-63. 10.1016/S1074-7613(02)00390-4.CrossRefPubMed
22.
Sandoval-Lopez G, Teran LM: TARC: novel mediator of allergic inflammation. Clin Exp Allergy. 2001, 31: 1809-12. 10.1046/j.1365-2222.2001.01268.x.CrossRefPubMed
23.
Lampinen M, Carlson M, Hakansson LD, Venge P: Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy. 2004, 59: 793-805. 10.1111/j.1398-9995.2004.00469.x.CrossRefPubMed
24.
Liaudet L, Szabo C, Evgenov OV, Murthy KG, Pacher P, Virag L, Mabley JG, Marton A, Soriano FG, Kirov MY, Bjertnaes LJ, Salzman AL: Flagellin from gram-negative bacteria is a potent mediator of acute pulmonary inflammation in sepsis. Shock. 2003, 19: 131-7. 10.1097/00024382-200302000-00008.CrossRefPubMed
25.
Monick MM, Yarovinsky TO, Powers LS, Butler NS, Carter AB, Gudmundsson G, Hunninghake GW: Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem. 2003, 278: 53035-44. 10.1074/jbc.M308093200.CrossRefPubMed
26.
Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET, Arditi M: Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol. 2001, 167: 1609-16.CrossRefPubMed
27.
28.
Betsuyaku T, Nishimura M, Takeyabu K, Tanino M, Venge P, Xu S, Kawakami Y: Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med. 1999, 159: 1985-91.CrossRefPubMed
29.
Finlay GA, Russell KJ, McMahon KJ, D'Arcy EM, Masterson JB, FitzGerald MX, O'Connor CM: Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax. 1997, 52: 502-6.PubMedCentralCrossRefPubMed
30.
Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T: TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol. 2003, 4: 161-7. 10.1038/ni886.CrossRefPubMed
31.
Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S: Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science. 2003, 301: 640-3. 10.1126/science.1087262.CrossRefPubMed
32.
Zhang G, Ghosh S: Negative regulation of toll-like receptor-mediated signaling by Tollip. J Biol Chem. 2002, 277: 7059-65. 10.1074/jbc.M109537200.CrossRefPubMed
33.
Li L, Cousart S, Hu J, McCall CE: Characterization of interleukin-1 receptor-associated kinase in normal and endotoxin-tolerant cells. J Biol Chem. 2000, 275: 23340-5. 10.1074/jbc.M001950200.CrossRefPubMed
34.
Hatao F, Muroi M, Hiki N, Ogawa T, Mimura Y, Kaminishi M, Tanamoto K: Prolonged Toll-like receptor stimulation leads to down-regulation of IRAK-4 protein. J Leukoc Biol. 2004, 76: 904-8. 10.1189/jlb.0504277.CrossRefPubMed
35.
Naiki Y, Michelsen KS, Zhang W, Chen S, Doherty TM, Arditi M: Transforming growth factor-beta differentially inhibits MyD88-dependent, but not TRAM- and TRIF-dependent, lipopolysaccharide-induced TLR4 signaling. J Biol Chem. 2005, 280: 5491-5. 10.1074/jbc.C400503200.CrossRefPubMed
36.
Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M, Lemon SM: Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A. 2005, 102: 2992-7. 10.1073/pnas.0408824102.PubMedCentralCrossRefPubMed
37.
Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, McMurray D, Smith DE, Sims JE, Bird TA, O'Neill LA: Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature. 2001, 413: 78-83. 10.1038/35092578.CrossRefPubMed
38.
Horng T, Barton GM, Flavell RA, Medzhitov R: The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature. 2002, 420: 329-33. 10.1038/nature01180.CrossRefPubMed
39.
Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T, Hoshino K, Takeuchi O, Kobayashi M, Fujita T, Takeda K, Akira S: Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature. 2002, 420: 324-9. 10.1038/nature01182.CrossRefPubMed
40.
Muzio M, Ni J, Feng P, Dixit VM: IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science. 1997, 278: 1612-5. 10.1126/science.278.5343.1612.CrossRefPubMed
41.
Kobayashi K, Hernandez LD, Galan JE, Janeway CA, Medzhitov R, Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell. 2002, 110: 191-202. 10.1016/S0092-8674(02)00827-9.CrossRefPubMed
Metadata
Title
Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly(I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response
Authors
Mirko Ritter
Detlev Mennerich
Andreas Weith
Peter Seither
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2005
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/1476-9255-2-16

Other articles of this Issue 1/2005

Journal of Inflammation 1/2005 Go to the issue

Research

Early relief of osteoarthritis symptoms with a natural mineral supplement and a herbomineral combination: A randomized controlled trial [ISRCTN38432711]

Research

Proanthocyanidins, from Ribes nigrum leaves, reduce endothelial adhesion molecules ICAM-1 and VCAM-1

Research

Heat shock protein and heat shock factor 1 expression and localization in vaccinia virus infected human monocyte derived macrophages

Research

Dexamethasone inhibits IL-9 production by human T cells

Research

CXCR2 is critical for dsRNA-induced lung injury: relevance to viral lung infection

Research

Differential signaling mechanisms regulate expression of CC chemokine receptor-2 during monocyte maturation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits